The #1 Cannabis Risk That No One Is Talking About

The cannabis industry hit its stride last year, with many pot stocks rising by 100% or more. In many ways, the exuberance is warranted. In 2018, Canada became the first industrialized country in the world to legalize recreational cannabis. Many U.S. states followed suit. Today, most states in the U.S. have some form of legal marijuana, even if it’s not…

Read More

Aurora Cannabis Inc. (TSX:ACB): Time to Buy This Marijuana Stock?

The latest round of earnings reports from Canadian cannabis producers has investors wondering which pot stocks might offer the best shot at additional upside through the end of 2019 and beyond. Let’s take a look at the current state of the sector and at Aurora Cannabis (TSX:ACB)(NYSE:ACB) to see if the stock deserves to be on your buy list. Ready,…

Read More

Aurora Cannabis (TSX:ACB) and Aphria (TSX:APHA) Get a Leg Up on the Competition

captor capital

Fort the most part, marijuana stocks have been bid up for one reason: the legalization of recreational marijuana in Canada. Pot stocks have sky-high valuations, and at the moment, their success as investments is dependent on this recreational demand. Lost amid the recreational hype is medical marijuana. Most pot stocks got their start as licensed medical marijuana producers. Major players,…

Read More

Marijuana Stocks: Is Cronos Group Inc. (TSX:CRON) a Buy?

It’s not too convincing to stay loyal to Cronos Group (TSX:CRON)(NASDAQ:CRON) stock after seeing its fourth-quarter earnings report. The marijuana producer has delivered sales much lower than market expectations, raising questions about its rich valuations. In a report released on March 26, Cronos reported that sales for the quarter, the first full period after Canada legalized recreational consumption, were $5.6…

Read More

Is Cronos Group Inc. (TSX:CRON) a Buy After Earnings?

Cronos Group (TSX:CRON)(NASDAQ:CRON) recently reported its much-anticipated fourth-quarter earnings report. The legalization of recreational marijuana happened in the midst of the company’s Q4 operations, and Cronos has been one of the best-performing pot stocks since the beginning of the year. Needless to say, expectations were high, but Cronos fell short of those expectations. Revenues soar. So do net losses On…

Read More

5 Takeaways From Cronos Group’s (TSX:CRON) Latest Quarterly Results

Canadian marijuana firm Cronos Group (TSX:CRON)(NASDAQ:CRON) released seemingly weak and unimpressive fourth-quarter and full-year 2018 financial results on Tuesday that exhibited non-disclosure of some information of interest and poor operating performance. A quarterly net revenue of $5.6 million represented a sequential revenue growth of just 49% from prior-quarter reading, while the competition did much better, even as average prices fell…

Read More